Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients.
Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients.
复制标题
鉴定和验证免疫相关 RNA 结合蛋白特征以预测神经胶质瘤患者的临床结果和治疗反应
DOI：
10.3390/cancers13071730
复制
发表时间：
2021-04-06
期刊：
影响因子：
5.2
通讯作者：
Shu M
中科院分区：
文献类型：
--
作者：
Tian R;Li Y;Liu Q;Shu M
简单概述肿瘤浸润性免疫细胞和RNA结合蛋白(RNAbindingProteins，RBPs)是影响脑胶质瘤患者预后的重要因素。然而，神经胶质瘤中的免疫相关限制性商业惯例仍未被研究。在这项研究中，我们开发了一种方法来识别与胶质瘤免疫渗透相关的限制性商业惯例，其中216种限制性商业惯例被定义为免疫相关限制性商业惯例。其中，8个RBPs被用来构建一个被证明是一个新的、独立的预后因素的风险签名。风险评分越高，总体存活率越低，人类白细胞抗原和免疫检查点的表达也越高。此外，还进行了途径丰富、体细胞突变、拷贝数变异和免疫/化疗反应预测的分析，以评估高风险组和低风险组之间的差异。总的来说，我们展示了八个免疫相关的RBPs预后标志，这在预测胶质瘤患者的生存和指导免疫治疗和化疗方面有价值。摘要胶质瘤患者的预后在很大程度上与肿瘤浸润性免疫细胞和RNA结合蛋白(RBP)的表达有关，RBP能够调节多种促炎和致癌介质。然而，神经胶质瘤中的免疫相关限制性商业惯例仍未被研究。在这项研究中，我们从癌症基因组图谱(TCGA)中获取患者数据，并根据免疫细胞渗透的不同将他们分为两个免疫亚型组。经过差异表达和共表达分析，我们鉴定出216个限制性商业惯例被定义为免疫相关限制性商业惯例。在缩小过程的范围后，选择了8个限制性商业惯例来构建风险签名，该签名被证明是一个新的独立的预后因素。根据危险评分将患者分为高风险组和低风险组。风险评分越高，总体存活率越低，人类白细胞抗原和免疫检查点(如PD1和CTLA4)的表达也越高。此外，还对高危组和低危组进行了途径丰富、体细胞突变、拷贝数变异和免疫/化疗反应预测分析，并进行了比较。我们首次展示了一个由8个免疫相关RBP组成的新信号，该信号在预测胶质瘤患者的生存和指导免疫治疗和化疗方面有价值。
Simple Summary Both of tumor-infiltrating immune cells and the RNA-binding proteins (RBPs) that are able to mediate immune infiltration contribute to the prognosis of patients with glioma. However, immune-associated RBPs in glioma remain unexplored. In this study, we developed a method to identify RBPs associated with immune infiltration in glioma and 216 RBPs were defined as immune-associated RBPs. Among them, eight RBPs were selected to construct a risk signature that proved to be a novel and independent prognostic factor. Higher risk scores meant worse overall survival and higher expression of human leukocyte antigen and immune checkpoints. Additionally, analyses of pathway enrichment, somatic mutation, copy number variations, and immuno-/chemotherapeutic response prediction were performed to evaluate the differences between high- and low-risk groups. Generally, we demonstrated an eight immune-associated RBPs prognostic signature that was valuable in predicting the survival of glioma patients and directing immunotherapy and chemotherapy. Abstract The prognosis of patients with glioma is largely related to both the tumor-infiltrating immune cells and the expression of RNA-binding proteins (RBPs) that are able to regulate various pro-inflammatory and oncogenic mediators. However, immune-associated RBPs in glioma remain unexplored. In this study, we captured patient data from The Cancer Genome Atlas (TCGA) and divided them into two immune subtype groups according to the difference in infiltration of immune cells. After differential expression and co-expression analysis, we identified 216 RBPs defined as immune-associated RBPs. After narrowing down processes, eight RBPs were selected out to construct a risk signature that proven to be a novel and independent prognostic factor. The patients were divided into high- and low-risk groups on the basis of risk score. Higher risk scores meant worse overall survival and higher expression of human leukocyte antigen and immune checkpoints such as PD1 and CTLA4. In addition, analyses of pathway enrichment, somatic mutation, copy number variations and immuno-/chemotherapeutic response prediction were performed in high- and low-risk groups and compared with each other. For the first time, we demonstrated a novel signature composed of eight immune-associated RBPs that was valuable in predicting the survival of glioma patients and directing immunotherapy and chemotherapy.
登录
查看更多内容
DOI：
10.1073/pnas.0503726102
发表时间：
2005-07-05
影响因子：
11.1
作者：
Klebanoff, CA;Gattinoni, L;Restifo, NP
通讯作者：
Restifo, NP
影响因子：
3.7
作者：
Hoshida Y;Brunet JP;Tamayo P;Golub TR;Mesirov JP
通讯作者：
Mesirov JP
影响因子：
15.9
作者：
Dolecek, Therese A.;Propp, Jennifer M.;Kruchko, Carol
通讯作者：
Kruchko, Carol
影响因子：
15.9
作者：
Cimino, Patrick J.;McFerrin, Lisa;Holland, Eric C.
通讯作者：
Holland, Eric C.
DOI：
10.1056/nejmoa1402121
发表时间：
2015-06-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Cancer Genome Atlas Research Network;Brat DJ;Verhaak RG;Aldape KD;Yung WK;Salama SR;Cooper LA;Rheinbay E;Miller CR;Vitucci M;Morozova O;Robertson AG;Noushmehr H;Laird PW;Cherniack AD;Akbani R;Huse JT;Ciriello G;Poisson LM;Barnholtz-Sloan JS;Berger MS;Brennan C;Colen RR;Colman H;Flanders AE;Giannini C;Grifford M;Iavarone A;Jain R;Joseph I;Kim J;Kasaian K;Mikkelsen T;Murray BA;O'Neill BP;Pachter L;Parsons DW;Sougnez C;Sulman EP;Vandenberg SR;Van Meir EG;von Deimling A;Zhang H;Crain D;Lau K;Mallery D;Morris S;Paulauskis J;Penny R;Shelton T;Sherman M;Yena P;Black A;Bowen J;Dicostanzo K;Gastier-Foster J;Leraas KM;Lichtenberg TM;Pierson CR;Ramirez NC;Taylor C;Weaver S;Wise L;Zmuda E;Davidsen T;Demchok JA;Eley G;Ferguson ML;Hutter CM;Mills Shaw KR;Ozenberger BA;Sheth M;Sofia HJ;Tarnuzzer R;Wang Z;Yang L;Zenklusen JC;Ayala B;Baboud J;Chudamani S;Jensen MA;Liu J;Pihl T;Raman R;Wan Y;Wu Y;Ally A;Auman JT;Balasundaram M;Balu S;Baylin SB;Beroukhim R;Bootwalla MS;Bowlby R;Bristow CA;Brooks D;Butterfield Y;Carlsen R;Carter S;Chin L;Chu A;Chuah E;Cibulskis K;Clarke A;Coetzee SG;Dhalla N;Fennell T;Fisher S;Gabriel S;Getz G;Gibbs R;Guin R;Hadjipanayis A;Hayes DN;Hinoue T;Hoadley K;Holt RA;Hoyle AP;Jefferys SR;Jones S;Jones CD;Kucherlapati R;Lai PH;Lander E;Lee S;Lichtenstein L;Ma Y;Maglinte DT;Mahadeshwar HS;Marra MA;Mayo M;Meng S;Meyerson ML;Mieczkowski PA;Moore RA;Mose LE;Mungall AJ;Pantazi A;Parfenov M;Park PJ;Parker JS;Perou CM;Protopopov A;Ren X;Roach J;Sabedot TS;Schein J;Schumacher SE;Seidman JG;Seth S;Shen H;Simons JV;Sipahimalani P;Soloway MG;Song X;Sun H;Tabak B;Tam A;Tan D;Tang J;Thiessen N;Triche T Jr;Van Den Berg DJ;Veluvolu U;Waring S;Weisenberger DJ;Wilkerson MD;Wong T;Wu J;Xi L;Xu AW;Yang L;Zack TI;Zhang J;Aksoy BA;Arachchi H;Benz C;Bernard B;Carlin D;Cho J;DiCara D;Frazer S;Fuller GN;Gao J;Gehlenborg N;Haussler D;Heiman DI;Iype L;Jacobsen A;Ju Z;Katzman S;Kim H;Knijnenburg T;Kreisberg RB;Lawrence MS;Lee W;Leinonen K;Lin P;Ling S;Liu W;Liu Y;Liu Y;Lu Y;Mills G;Ng S;Noble MS;Paull E;Rao A;Reynolds S;Saksena G;Sanborn Z;Sander C;Schultz N;Senbabaoglu Y;Shen R;Shmulevich I;Sinha R;Stuart J;Sumer SO;Sun Y;Tasman N;Taylor BS;Voet D;Weinhold N;Weinstein JN;Yang D;Yoshihara K;Zheng S;Zhang W;Zou L;Abel T;Sadeghi S;Cohen ML;Eschbacher J;Hattab EM;Raghunathan A;Schniederjan MJ;Aziz D;Barnett G;Barrett W;Bigner DD;Boice L;Brewer C;Calatozzolo C;Campos B;Carlotti CG Jr;Chan TA;Cuppini L;Curley E;Cuzzubbo S;Devine K;DiMeco F;Duell R;Elder JB;Fehrenbach A;Finocchiaro G;Friedman W;Fulop J;Gardner J;Hermes B;Herold-Mende C;Jungk C;Kendler A;Lehman NL;Lipp E;Liu O;Mandt R;McGraw M;Mclendon R;McPherson C;Neder L;Nguyen P;Noss A;Nunziata R;Ostrom QT;Palmer C;Perin A;Pollo B;Potapov A;Potapova O;Rathmell WK;Rotin D;Scarpace L;Schilero C;Senecal K;Shimmel K;Shurkhay V;Sifri S;Singh R;Sloan AE;Smolenski K;Staugaitis SM;Steele R;Thorne L;Tirapelli DP;Unterberg A;Vallurupalli M;Wang Y;Warnick R;Williams F;Wolinsky Y;Bell S;Rosenberg M;Stewart C;Huang F;Grimsby JL;Radenbaugh AJ;Zhang J
通讯作者：
Zhang J